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A B S T R A C T

Background: The mycobiome is the fungal component of the gut microbiome and is implicated in several
autoimmune diseases. However, its role in MS has not been studied.
Methods: In this case-control observational study, we performed ITS sequencing and characterised the gut
mycobiome in people with MS (pwMS) and healthy controls at baseline and after six months.
Findings: The mycobiome had signiﬁcantly higher alpha diversity and inter-subject variation in pwMS than
controls. Saccharomyces and Aspergillus were over-represented in pwMS. Saccharomyces was positively correlated with circulating basophils and negatively correlated with regulatory B cells, while Aspergillus was
positively correlated with activated CD16+ dendritic cells in pwMS. Different mycobiome proﬁles, deﬁned as
mycotypes, were associated with different bacterial microbiome and immune cell subsets in the blood. Initial
treatment with dimethyl fumarate, a common immunomodulatory therapy which also has fungicidal activity, did not cause uniform gut mycobiome changes across all pwMS.
Interpretation: There is an alteration of the gut mycobiome in pwMS, compared to healthy controls. Further
study is required to assess any causal association of the mycobiome with MS and its direct or indirect interactions with bacteria and autoimmunity.
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Research in context
Evidence before this study
Many studies reported that the gut bacterial microbiome plays
an important role in MS. The gut mycobiome is the fungal component of the microbiome, which characteristics
such as
compositions, abundances, and interaction with the immune
system in pwMS have not been studied yet.
Added value of this study
This is the ﬁrst study that comprehensively characterised the
gut mycobiome in pwMS and healthy controls, at baseline and
after six months. We found altered fungal compositions and
diversity in pwMS, and we evaluated mycobiome short-term
stability. We also found speciﬁc fungi-bacteria communities
associations, and a number of novel fungi-immune, and fungidiet correlations.
Implication of all the available evidence
Our ﬁndings bring a new perspective in studying the entire
microbiome in MS, highlighting a potentially important role of
mycobiome in MS and its interactions with host’s immune and
dietary factors.

that fungi may be involved in the pathogenesis of MS. For example, a
conserved epitope within fungi may trigger autoimmune response in
the host through molecular mimicry or epitope spreading mechanisms
[35]. In addition, HLA-DRB1*15 allele group, the most important genetic
risk factor of MS, is associated with increased sensitivity to infection by
Aspergillus fumigatus [36], a commensal fungus commonly found in the
gut [37]. Furthermore, C. albicans induces encephalitogenic cytokines
production in the periphery and CNS, resulting in severe disease course
in a murine MS model [38]. Interestingly, dimethyl fumarate, a fungicide
repurposed as a disease-modifying therapy (DMT) for MS, reduces the
MS relapse rate [39]. These ﬁndings support the view of fungi as infectious agents that are potentially involved in the development of MS.
However, to date, a comprehensive characterization of gut commensal
mycobiome is lacking in people with MS (pwMS). It is also unclear if the
gut mycobiome is affected by diet or other clinical characteristics of
pwMS, and how they interact with gut bacterial microbiome and host
immune response.
We hypothesise that the gut mycobiome is altered in pwMS considering the evidence of mycobiome changes in other autoimmune diseases, immune regulatory properties of the mycobiome, and bacteriafungi interaction in the gut. We longitudinally characterised the mycobiome in a cohort of pwMS and healthy controls over six months.
Herein, we report altered gut mycobiome composition and diversity in
pwMS not on DMT compared to healthy controls at baseline, and mycobiome stability over time in pwMS. We identiﬁed correlations of the gut
mycobiome with bacterial microbiota, peripheral immune responses,
and dietary patterns. We demonstrated a disrupted mycobiome-autoimmune pattern in pwMS compared to healthy controls.

1. Introduction

2. Methods

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) with an elusive aetiology. The gut microbiome has a strong capacity to modulate host’s local and systemic
immune responses, and has been postulated to be an essential player in
MS pathogenesis as well as a novel therapeutic target [1]. Previous
work on the role of the microbiome largely focused on the bacterial
microbiota, while the characteristics of other important components of
the microbiome, such as fungi, remain undeﬁned in MS [2 4].
The diverse population of fungi residing in the gastrointestinal
tract is collectively termed the gut mycobiome. It accounts for »0¢1%
of gut microbiota and is ubiquitous in all human populations [5,6].
Saccharomyces, Malassezia and Candida are the three major fungal
genera in the healthy human gut [5]. Although the mycobiome cocolonizes with bacterial microbiome, mycobiome-bacteria and mycobiome- host interactions have not been well studied. Several studies
suggest mutual or competitive relationships between gut mycobiome
and bacteria [7]. The mycobiome produces alcohol, antimicrobial
peptides, and other metabolites that affect bacteria colonization
[8,9]. Bacteria, in turn, generate fatty acids that regulate fungal germination and hyphal growth [10,11]. The commensal mycobiome, such
as Candida albicans or Saccharomyces cerevisiae, can alleviate gut
mucosal injuries from dextran sodium sulphate (DSS)-induced colitis
in mice and exhibit immune modulatory properties [12], suggesting
the mycobiome ability to maintain gut homeostasis. In contrast, Saccharomyces can exacerbate gut inﬂammation and increase gut permeability in an animal model of inﬂammatory bowel disease (IBD)
through overproduction of uric acid [13].
The gut mycobiome proﬁle varies, depending on age, gender, diet,
medication, and disease status. Dysbiosis of the gut mycobiome has
been implicated in various human metabolic or autoimmune conditions
including IBD [14 16], irritable bowel syndrome (IBS) [17,18], cancer
[19 21], hepatitis B and HIV infections [22 25], and alcoholic liver disease [26]. It is also linked to neurological disorders including Rett syndrome (RTT) [27,28], autism spectrum disorders [29 31], and
schizophrenia [32 34]. Multiple lines of evidence suggest the possibility

2.1. Ethics
The study was approved by the Human Research Protection Ofﬁce
at Washington University in St. Louis School of Medicine (WUSM)
(approval number: 201502105). All patients gave informed consent
to participation.
Subject enrolment and sample collections
People with MS were recruited at the John L. Trotter MS Center at
WUSM from October 2015 to June 2017. Inclusion criteria for participating in the study were:
(1) diagnosis of MS using the 2010 revision of the McDonald criteria; (2) no DMT or steroid treatments in the past 3 months; (3) ages
18 to 50 years; and (4) not in clinical relapse at study enrolment.
Exclusion criteria were: (1) coexistence of other chronic inﬂammatory (e.g. asthma, chronic hepatitis, inﬂammatory bowel disease,
celiac disease) and autoimmune (e.g. rheumatoid arthritis, systemic
lupus erythematosus, type I diabetes), or metabolic (e.g. type II diabetes, familial hypercholesterolemia) diseases; (2) antibiotics or steroid
therapy in the past 3 months; (3) history of immunosuppressive or
chemotherapeutic treatment;
(4) history of chronic infectious disease (e.g. TBC, HIV, HBV, HCV);
(5) neoplastic disease not in complete remission, and (6) pregnancy.
Age, gender, BMI, and ethnicity matched healthy controls were
enrolled using the same exclusion criteria. After six months, pwMS
gave another sample (Supplementary Fig. 1). No relapse was reported
in all MS patients during the study period. This was a pilot study and
since no previous study was done on the mycobiome in MS, no power
calculation was performed.
2.2. Stool collection, mycobiome sequencing, and data processing
Stools were self-collected and shipped on frozen gel packs overnight to the research laboratory. The stools were stored in -80°C until
DNA extraction. DNA extraction of the stool samples was conducted
using the MOBIO PowerSoil DNA Extraction kit. The gut mycobiome
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was proﬁled by ITS1 amplicon sequencing using primer sets (ITS: F’
(18S-F)
GTAAAAGTCGTAACAAGGTTTC, R’ (5¢8S-1R)
GTTCAAAGAYTCGATGATTCAC) with inbuilt
Illumina adapters and barcodes. Dual indexed paired-end ITS1
libraries were made using AccuPrime HiFi Taq (Cat # 12346094, Thermoﬁsher Scientiﬁc). ITS1 libraries were prepared and sequenced on
the Illumina MiSeq sequencing platform using v3-600 cycle reagents
(cat # MS-102 3003, Illumina Inc.) paired end sequencing protocol
with a target read depth of 10,000 reads/sample.
Sequences from each sample were trimmed of primers and lowquality bases using Trimmomatic. Paired end trimmed reads were
assembled using FLASH. Host contaminant/Chimera sequences were ﬁltered out using BMTagger and Usearch/Uchime respectively. The processed and cleaned ITS1 sequences were classiﬁed from phylum to genus
level using UNITE database (https://unite.ut.ee/repository.php).
2.3. Blood collection and immunophenotyping
Blood was collected in heparinized tubes, insulated, and shipped at
room temperature overnight. Peripheral blood mononuclear cells
(PBMCs) were isolated immediately on arrival for immunophenotyping.
We used seven ﬂow cytometry antibody panels to analyse lymphocyte
and monocyte populations. Panel A included: V450-CD3 (UCHT1),
PECy7-CD19 (SJ25C1), FITC-CD56 (NCAM16¢2), and APC-H7-CD27 (MT271). Panel B included: V450-CD3 (UCHT1), V500- CD4 (L200), PECy7CD8 (RPA-T8), APC-CD45RA (HI100), and APC-H7-CD27 (M-T271). Panel
C included: V450-CD3 (UCHT1), V500-CD4 (L200), FITC-CD25 (M-A251),
and PE-FOXP3 (PCH101). Panel D included: V450-CD3 (UCHT1), V500CD4 (L200), PECy7-CD8 (RPA-T8), APC-CD45RA (HI100), FITC-Tbet
(4B10), PE- IFNg (4S.B3), PerCP-Cy5¢5-GMCSF (BVD2-21C11), and APCCy7- IL17 (BL168). Panel E included: V450-CD3 (UCHT1), PECy7-CD19
(SJ25C1), PerCP-Cy5¢5-CD5 (L17F12), PE-CD1d (42¢1), APC-H7-CD27
(M-T271), FITC-IL10 (BT-10), and APC-IL35/27(EB13). Panel F included:
V450-CD3 (UCHT1), V450-CD19 (SJ25C1), PE-HLA-DR (G46-6), PE-Cy7CD11c (B- ly6), PerCP-CD14 (M’P9), APC-CD123 (7G3), and FITC-BDCA2
(201A). Panel G included: V450-CD3 (UCHT1), V450-CD19 (SJ25C1), PEHLA-DR (G46-6), PE-Cy7-CD11c (B-ly-6), PerCP-CD14 (M’P9), APCCD16 (B73¢1), and APC-H7-CD80 (L307¢4). For panel D, the PBMCs were
stimulated with 50 ng/ml of PMA (Sigma cat#16561-29-8) and 1 mg/ml
of ionomycin (Sigma cat#I0634), and treated with 0¢2ul of Golgi plug
(BD cat#555029) for four hours before staining. For Panel E, we stimulated PBMCs with 50 ng/ml of PMA (Sigma cat#16561-29-8), 1 mg/ml of
ionomycin (Sigma cat#I0634), and CpG for four hours before staining.
Gating strategy can be found in (Supplementary Fig. 2).
2.4. Food frequency questionnaire
A food-frequency questionnaire was self-recorded on four consecutive days (two weekend days and two weekdays) before the stool
sample collection at baseline and at six months. The food diary was
converted to daily food serving based on the Nutrition Coordinating
Center (NCC) Food Group Serving Count System.
2.5. Statistics
ITS1 sequences in each sample were rareﬁed to 10,000 reads to
correct for uneven sample depths and then converted to relative
abundances. Descriptive and formal statistical tests were performed
to understand the mycobiome compositions, their difference
between groups, correlations with diet and immune-phenotype.
Descriptive analysis. The mean relative abundances of the mycobiome were used to show the overall compositions of the stool mycobiome at genus level and phylum by barplot. The most abundant 20
genera were shown, including Unclassiﬁed fungi genera as one group.
The barplots of MS patients from baseline to six months later were also
shown to depict which and how the fungi genera changed. The fungi
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difference in obesity boxplots were determined by classifying patients’
BMI as normal (BMI < 25), overweight (BMI between 25 and 30), and
obese (BMI > 30). The top 25 fungi were tested to ﬁnd a difference
between obese (BMI > 30) and non-obese (BMI < 30) samples.
Mycobiome diversity. Alpha diversity was evaluated by richness
and Shannon diversity at genus level. To test inter-subject variation
between MS and controls, beta diversity was measured using betadisper function in vegan package in R.
High dimension data analysis. Nonmetric multidimensional scaling
(NMDS) was used to view sample cluster patterns (similarity
between samples). The metaMDS function from the vegan package
and the isoMDS from the MASS package found the nonmetric multidimensional scaling (NMDS) of our samples’ Bray-Curtis dissimilarity
matrices. Statistical signiﬁcance of the overall mycobiome structure
between compared groups or variables were conducted by PERMANOVA using Adonis function in Vegan package.
Wilcoxon sum rank test. Wilcoxon sum rank test was conducted to
compare alpha diversity of MS and controls, identiﬁcation of speciﬁc
mycobiome (at least 1% mean abundance) difference between MS
and controls at baseline, and identiﬁcation of bacterial difference (at
least 5% bacterial mean abundance) or immune cells population or
cytokine difference between two mycotypes. To compare the mycobiome changes (at least 1% mean abundance) from baseline to six
months, a paired sample t-test was conducted.
Pearson correlations. Correlation analysis were performed for two
continuous variables correlation. Correlations with correlation coefﬁcient r < -0¢3 or r > 0¢3 were reported. The p-values were less than
0¢05 in all reported correlations. All the correlations were manually
inspected by plotting raw data and correlations driven by one or two
data points were not reported. P-values for correlations were found
with the cor.test from the stats package. Relative abundances of fungi
genera were correlated with bacteria genera and dietary servings,
using both baseline MS and controls samples without discriminating.
Immune correlations were done with combined MS and healthy controls as well as separately for MS and controls since MS as an autoimmune disease was likely to have different immune factors from
controls (Fig. 6a c). Heatmap was used to view correlations.
Gut mycotype identiﬁcation. Mycotypes were determined with the
“mclust” package based on Gaussian mixture models. The two mycotypes were selected based on Bayesian Information Criteria [40]. Top
20 most abundant mycobiome genera were used to build the model.
Barplots were used to show the mean relative abundances of mycobiome in each mycotype.
All plots were made with “ggplot2” and formatted with “ggpubr”
except for heatmaps made with “pheatmap”. “Vegan” (v. 2¢5 6) was
used for count rarefaction, Shannon diversity, specnumber, beta dispersion, Adonis, mantel, and Bray-Curtis dissimilarity. All p-values
from multiple comparisons were adjusted with false discovery rate
method. All analysis was done in RStudio version 1¢2¢1.
2.6. Role of funding source
The funders had no role in the conceptualization, study design,
data collection, analysis, interpretation of data, in writing the paper,
or in the decision to submit the paper for publication.
3. Results
3.1. Study population
Twenty-ﬁve pwMS and 22 healthy controls included in this analyses were recruited for the study at Washington University School of
Medicine in St. Louis. None of the pwMS was having a relapse at time
of enrolment or had received any DMTs or steroid treatment in the
previous three months. Of the 25 pwMS, 21 were diagnosed with
relapsing-remitting MS (RRMS), 2 with primary progressive MS
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Fig. 1. Mycobiome compositions in pwMS and control groups, based on ITS1 sequencing analysis. (a) Mean relative abundances of fungi phyla. “Unclassiﬁed” represent unknown
fungal phyla. (b) Mean relative abundances of the 20 most abundant fungi genera. “Unclassiﬁed” represents unknown fungal genera.

(PPMS), 1 with secondary progressive MS (SPMS), and 1 with clinical
isolated syndrome (CIS). Mean disease duration at study entry was 4¢9
(SD 6¢6) years. Except for the MS group using more tobacco
(P < 0¢0005, chi-square test), the characteristics of the control and MS
groups were similar (Supplementary Table 1). Stool and blood samples
were collected at entry (baseline) and after six months for the gut
mycobiome and blood immune cell analyses, respectively. A four-day
food-frequency questionnaire was also recorded to provide qualitative
dietary information at baseline and at six months for all participants.
3.2. Altered mycobiome compositions and diversity in non-treated MS
patients
ITS1 sequencing yielded a range of 1146 2,517,870 reads/sample
(mean = 61,986 and median = 11,863). We ﬁrst examined the gut mycobiome composition in pwMS and healthy control individuals at baseline.
We considered pwMS in one single group. Separate analysis with exclusion of non-RRMS patients in the study did not change the results. At
the phylum level, 92¢5% of phyla were identiﬁed. Ascomycota and Basidiomycota were the two predominant phyla in both pwMS and controls,
together accounting for over 80% of total mycobiome population. At the
genus level, we identiﬁed 59 genera, of which 25 (excluding the unclassiﬁed fungi shared between the two groups) made up 48% of the total
relative abundances (Fig. 1). Of the unclassiﬁed genera, 61¢7% belonged
to the phylum Ascomycota and 36¢2% belonged to Basidiomycota. Saccharomyces, Xylaria, Pencillium, Agaricus, and Aspergillus were the top
ﬁve most abundant classiﬁed fungi in the gut in both groups. On average, Saccharomyces composed 23% and 42% of the gut mycobiome in
control and pwMS, respectively.
To assess overall mycobiome community differences between
pwMS and controls, we performed non- metric multidimensional
scaling (NMDS, Fig. 2a) at the genus level. Permutational multivariate
analysis of variance (PERMANOVA) analysis showed that the overall
mycobiome community differed between pwMS and controls
(p=0¢04). Further dispersion analysis revealed that the difference in
mycobiome between pwMS and the healthy controls is likely due to
pwMS having higher inter-subject variation than control participants
(beta disper, p < 0¢03). Speciﬁc analysis indicated that pwMS samples
had greater proportions of Aspergillus (p=0¢008, padj=0¢02, Wilcoxon)
and Saccharomyces (p=0¢005, padj=0¢02, Wilcoxon) (Fig. 2b). The variance of Saccharomyces was signiﬁcantly higher in pwMS than those in

controls (p=0¢0004, Levene test). Notably, Unclassiﬁed genera were
overall more abundant in healthy controls than MS samples (p=0¢05,
padj=0¢088, Wilcoxon, data not shown). No phylum was signiﬁcantly
different between samples from pwMS and controls.
Stools from pwMS had signiﬁcantly greater mycobiome richness
(p=0¢041, Wilcoxon) and Shannon diversity (p=0¢043, Wilcoxon)
(Fig. 2c) than stools from controls, suggesting overgrowth of different
types of fungi in the gut mycobiome in pwMS. There were 18 genera
exclusive to pwMS samples. For example, Phlebia and Rhizopus were
each detected at very low abundances, but in pwMS samples only.
Our ﬁndings are consistent with the data in a study of subjects with
Crohn’s disease, another putative autoimmune disorder, in which
was also shown to have increased fungal diversity and richness compared to healthy controls [14].
3.3. Mycobiome remains stable over six months
We next investigated the stability of the mycobiome in pwMS. We
found that overall mycobiome structure did not change signiﬁcantly
over six months (Fig. 3a, p=0¢085, PERMANOVA). The alpha diversity
did not signiﬁcantly change between the two time points (Shannon
index p=0¢36, richness p=0¢25, Wilcoxon). However, there were high
inter-individual variations in the dynamics of the mycobiome (Supplementary Fig. 3a). On average, we found that Saccharomyces
decreased in six months (p=0¢01, padj=0¢076, Paired T- test). Our
ﬁndings are consistent with the notion that the most abundant and
common species continue to dominate over time even in samples
with high fungal variability [5].
Eleven pwMS started treatment with DMTs in the six months after
baseline samples were obtained. We did not identify a distinct mycobiome between patients treated with DMTs (n=11) compared to
those who were not-treated (n=9) at six months (Fig. 3b, p=0¢79, PERMANOVA). We also did not ﬁnd a difference in the mycobiome
between baseline and six months for pwMS who began DMT treatments within six months (p=0¢22, PERMANOVA, Fig. 3c). We additionally compared the mycobiome changes in three pwMS who
received dimethyl fumarate (DMF), a DMT with fungicidal properties,
but found no consistent changes in genus abundances nor alpha
diversity after treatment (at the six-month point) (Supplementary
Fig. 3b). Further research into DMF’s effect on the gut mycobiome
with a larger sample size would be warranted.
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Fig. 2. Mycobiome diversity in pwMS and control groups. (a) NMDS plot of the Bray-Curtis dissimilarity of control and pwMS based on the mycobiome proﬁle (p = 004). (b) Relative
abundance of Aspergillus (p = 0008, padj= 002) and Saccharomyces (p = 0005, padj = 002) in the two groups. (c) Alpha diversity variation between the two groups, expressed as
Shannon diversity and observed richness.

3.4. Interactions between the gut mycobiome and bacterial microbiome
To investigate relationships between fungi and bacteria in the gut,
we performed Pearson correlations with all participants at baseline. We
found a high correlation between Mucor and Fusicatenibacter (Fig. 4a,
r=0¢81, p < 0¢001). Fusicatenibacter is a bacterial genus belonging to
Clostridium cluster XIV and Lachnospiraceae incertae sedis. The abundance
of the bacterial genus Prevotella highly correlated with the fungi Hannaella (r=0¢62, p < 0¢001) and Derxomyces (r=0¢39, p=0¢019), both of
which are low in abundances. Alistipes, one bacterial genus that is associated with MS [41], was positively correlated with Penicillium (r = 0¢68,
p < 0¢001). When MS and control samples were separated, Saccharomyces which had notably greater abundance in MS samples, was negatively
correlated with Lachnospiracea incertae sedis (r=-0¢48, p=0¢04) in pwMS.
In controls alone, Saccharomyces and Oscillibacter were positively correlated (r = 0¢51, p=0¢029).
We next asked if different mycobiome proﬁles are associated with
speciﬁc microbiome compositions. The gut microbiome can be classiﬁed into three types (termed enterotypes) based on their relative abundances [42,43], which are associated with different health and disease
conditions. Using the Mclust method, we classiﬁed the mycobiome proﬁle into two fungal clusters (“mycotypes”) which had a similar ratio of
MS and controls (Supplementary Fig. 4). Mycotype 1 consists of 11 controls and 13 pwMS, whereas Mycotype 2 has seven controls and ﬁve
pwMS. Mycotype 1 was dominated by unclassiﬁed genera and Saccharomyces, whereas Mycotype 2 shows greater diversity and reduced

Saccharomyces, and a higher average proportion of Penicillium, Malassezia, and Mucor (Fig. 4b). Comparison of the relative abundances of the
bacteria in participants from the two mycotypes (Fig. 4c) demonstrated
that the Bacteroides (p=0¢026, padj =0¢055, Wilcoxon) and Unclassiﬁed
Ruminococcaceae (p=0¢029, padj =0¢055, Wilcoxon) were greater in participants from Mycotype 1 whereas Unclassiﬁed Lachnospiraceae was
signiﬁcantly greater in participants from Mycotype 2 (p=0¢033, padj
=0¢055, Wilcoxon, Fig. 4d). The latter ﬁnding is consistent with data
presented in Fig. 4a that reports a positive correlation between Penicillium and Malassezia and Unclassiﬁed Lachnospiraceae family. These
results suggest that distinct mycobiome proﬁles are associated with
distinct bacterial compositions.
3.5. Correlations of the diet and body mass index with the gut
mycobiome
We further determined the effect of diet on the gut mycobiome
using baseline data from all participants. All types of food intake
were similar in MS and control groups except that the MS group had
signiﬁcantly more meat (p=0¢019, Wilcoxon). However, meat had no
signiﬁcant impact on the gut mycobiome variation (p=0¢17 padj=0¢47,
PERMANOVA). We performed PERMANOVA analysis and identiﬁed
four types of food intakes that are potentially associated with the gut
mycobiome community structure (Fig. 5a): ‘butter and animal fats’
(p=0¢003, padj =0¢069), ‘nuts and seeds’ (p=0¢016, padj =0¢18),
‘reﬁned grain’ (p=0¢04, padj=0¢18), and ‘whole grain’ (p=0¢042,
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Fig. 3. Longitudinal stability of the mycobiome. (a) NMDS plot of Bray-Curtis dissimilarity of the mycobiome proﬁle of pwMS samples taken at baseline and at six months
(p = 0085). (b) NMDS of Bray-Curtis dissimilarity of pwMS treated or not treated with DMTs at six months (n = 20, p = 079). (c) NMDS of baseline (n = 11) and six- months (n = 11)
for pwMS who received DMT treatments within six months (p = 022).

padj =0¢18). Speciﬁcally, the Pearson correlations of food servings and
fungal genera abundances showed that Saccharomyces (r = 0¢42,
p=0¢008, Pearson) and Hannaella (r = 0¢38, p=0¢02, Pearson) each had
a moderately strong positive correlation with ‘butter and animal
fats’, whereas Saccharomyces has a negative correlation with ‘nuts
and seeds’ (r = -0¢38, p=0¢022, Pearson) and ‘whole grain’ servings
(r = -0¢35, p= 0¢037). Hannaella also has a moderately strong correlation with ‘ﬁsh and shellﬁsh’ servings (r = 0¢59, p= 0¢0005, Pearson).
Aspergillus had a positive correlation with ‘eggs’ (r= 0¢39, p= 0¢002)
and ‘reﬁned grain’ serving (r = 0¢41, p= 0¢011) and negative correlation with ‘whole grain’ servings (r= -0¢31, p=0¢04). In pwMS only,
some of the aforementioned correlations became stronger: Saccharomyces and ‘nuts and seeds’ (r = -0¢51, p=0¢012); Hannaella and ‘butter
and animal fats’ (r= 0¢59, p=0¢003); Aspergillus and ‘eggs’ (r= 0¢55,
p=0¢006) and ‘reﬁned grain’ (r= 0¢57, p=0¢005). In controls only, Hannaella strengthened its correlation with ﬁsh (r= 0¢75, p= 0¢0007) but
lost it with ‘eggs’ servings (r= 0, p=0¢93).
Obesity is associated with mycobiome dysbiosis [44]. We found
that Hannaella had a moderately strong positive correlation with BMI
(r = 0¢52, p < 0¢001, Pearson). In our study, 21 subjects were classiﬁed
as normal weight (BMI < 25), 11 were overweight (25  BMI < 30),
and 12 were obese (BMI  30). The proportions of pwMS and controls
who were obese, overweight, and normal weight were similar
between the two groups (p=0.803, chi-squared test). The relative
abundance of Hannaella (p=0¢0033, Wilcoxon), Saccharomyces
(p=0¢037), and Derxomyces (p=0¢005) was signiﬁcantly higher in
obese subjects than non- obese (Fig. 5b). No genus was found to be

different between normal and overweight individuals, indicating that
mycobiome alteration occurred primarily in the obese vs non-obese
level (Supplementary Fig. 5).
3.6. Correlation of the gut mycobiome with peripheral blood immune
proﬁles
We have previously shown in the cohort of subjects studied
herein, that the percentages of peripheral blood IL-10+ memory B
cells, T-bet+ memory and effector T cells, memory and effector Th17
cells were signiﬁcantly greater in MS than in control individuals
(Supplementary Table 2, and [Cantoni, unpublished]). We next asked
if and to what extent the gut mycobiome is associated with peripheral blood immune proﬁle. We determined the correlations between
the mycobiome compositions and the peripheral immune cell proﬁles in the whole cohort of pwMS and controls, or in the pwMS or
control groups separately. Pearson correlation of fungi genera and
immune cell subsets using all baseline samples (Fig. 6a) showed that
Mucor had a positive correlation with effector CD4+ T Cells (r=0¢52,
p=0¢0003, Pearson) and effector CD8+ T Cells (r=0¢51, p=0¢0004). Hannaella had a positive correlation with memory CD4+ T cells producing
GM- CSF (r=0¢53, p=0¢0003). Additional positive correlations were
found between NK cells, CD56low/CD56high NK cells and genera
Debaryomyces (r=0¢59, p=0¢0005), Malassezia (r=0¢54, p=0¢0001), and
between regulatory B cells and Penicillium (r=0¢67, p=0¢005). Saccharomyces showed a negative correlation with effector Th1 cells (r=0¢37, p=0¢02) and a positive correlation with activated CD16+/ DCs
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Fig. 4. Association between fungal and bacterial microbiome. (a) Heatmap shows fungi-bacteria Pearson correlations. Nonsigniﬁcant correlations are omitted. (b) Mean relative
abundances of the major fungi in two mycotypes identiﬁed by Mclust Gaussian Mixture analysis (n1 = 24, n2 = 12). (c) Mean relative abundances of the gut bacteria in participants
belonging to the two mycotypes. (d) Signiﬁcantly over-represented gut bacteria between two mycotypes: Bacteroides (p = 0026, padj = 0055), unclassiﬁed Ruminococcaceae
(p = 0029, padj = 0055), and Lachnospiraceae (p = 0033, padj = 0055).

(r=0¢31, p=0¢03). Aspergillus was positively correlated with total B
cells (r=0¢35, p=0¢01) and CD16+ dendritic cells (r=0¢32, p=0¢03).
Analyses in pwMS and controls separately revealed group speciﬁc
correlations between the mycobiome compositions and peripheral
immune proﬁles. Interestingly, the number of total correlations (positive or negative) identiﬁed in MS were 1¢7 fold less, compared with
controls, indicating a disrupted immune- mycobiome interaction. We
showed that Saccharomyces and Aspergillus were over-represented in

pwMS compared to controls (Fig. 2b). In the MS group, Saccharomyces
was positively correlated with the frequency of basophils (r=0¢50,
p=0¢015, Pearson) and negatively correlated with regulatory B cells
(r=- 0¢49, p=0¢03). Aspergillus was positively correlated with activated
DCs (r=0¢57, p=0¢004) and total B cells (r=0¢50, p=0¢014). Penicillium
was positively correlated with regulatory B cells (r=0¢54, p=0¢018,
Fig. 6b). In the control group, Saccharomyces was negatively correlated with CD4+ naïve T cells (r=-0¢43, p=0¢045) and positively
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Fig. 5. Diet and the mycobiome. (a) Heatmap shows Pearson correlations between food servings and fungi genera. Nonsigniﬁcant correlations are omitted. (b) Relative abundance of
Hannaella, Saccharomyces, and Derxomyces in obese (BMI  30) and non-obese participants (BMI < 30).

correlated with CD16 DCs (r=0¢50, p=0¢018). Malassezia had the
greatest positive correlation with Th17 cells (r=0¢59, p=0¢004, Pearson)
and positively or negatively correlations with six additional immune
cell populations (Fig. 6c). Malassezia was the fungal genus with the
most frequent interaction with the immune proﬁles in healthy controls. These connections disappeared completely in pwMS.
Comparison of the immune proﬁle difference between the two
mycotypes revealed that effector memory CD4+ T cells were greater
in mycotype 2 than in mycotype 1 (p=0¢038, Wilcoxon, Fig. 6d).
Mycotype 2 was characterised by greater fungi diversity (Fig. 6d).
4. Discussion
This study is the ﬁrst to deﬁne the gut mycobiome of pwMS. Both
pwMS and controls were dominated by Saccharomyces, Xylaria, and
Penicillium. Nash et al. identiﬁed Saccharomyces (»20% relative abundance), Malassezia (4% relative abundance), and Candida (2% relative
abundance) as the dominant genera in healthy samples [5], while
Hoffman et al. identiﬁed Saccharomyces, Candida, and Cladosporium
as the most abundant in healthy control samples [45]. In our study,

Saccharomyces was most abundant genera (23% in control and 42% in
MS), while Candida and Malassezia only account for 0¢26% and 0¢86%,
respectively, and Cladosporium was not detected at all. Environment,
diet, and exposure to different climates could also play a role in the
fungi colonization of the gut [46,47]. We recruited participants from
St Louis, whereas Nash et al. recruited from Pennsylvania, and Hoffman et al. from Houston. In addition, DNA extraction and sequencing
regions may also contribute to mycobiome differences across studies,
suggesting the need for a standardized mycobiome characterization.
We compared mycobiome diversity and compositions in pwMS
and healthy control samples. Overall, the results indicate that samples from pwMS had higher mycobiome diversity and greater intersubject variation compared to the mycobiome of healthy controls.
These ﬁndings are in contrast with most of the studies on the bacterial microbiome in MS patients including our own study from the
same study cohort [Cantoni, unpublished], in which bacterial diversity was similar between MS patients and healthy controls. Microbial
diversity is an indicator of gut health, and it is generally determined
by the bacterial diversity. Higher bacterial diversity is associated with
healthier gut ecosystem. Infection or disease conditions, high fat diet
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Fig. 6. Correlation between the mycobiome and blood immune proﬁles. Pearson correlations between immune cell populations and fungi genera at baseline for (a) pwMS and controls, (b) pwMS only, and (c) controls only. Nonsigniﬁcant correlations are omitted. (d) Relative abundance of effector memory CD4 T cells between mycotypes.

or inﬂammatory immune response in the gut decreases microbial
diversity [48]. Our data suggest that the mycobiome diversity is an
important indicator of the gut microbial diversity in MS patients, and
may be more sensitive than the bacterial diversity in response to MS
associated gut microbiome changes.
The gut mycobiome accounts for less than one percent of the entire
microbiome, therefore it may be considered rare relative to the bacterial
microbiome [49]. However, rare biosphere can have disproportionate
effects on health and diseases [50]. We found two commensal gut fungal
genera Saccharomyces and Aspergillus that were more abundant in MS.
Saccharomyces is called the baker and brewer's yeast for its role in food
fermentation, as well as commonly being used as a gut probiotics [51].
However, the biological role of Saccharomyces in health and diseases is
inconsistent across studies, with either protective or detrimental effect
on the gut inﬂammation in animal model of IBD [12,13]. MS and IBD
share similar epidemiological, immunological, and gut bacterial microbiome characteristics [52]. Our results support a pathogenic correlation
of Saccharomyces with MS. In addition, Saccharomyces had positive correlations with ‘butter and milk’ servings and higher relative abundance
in obese participants. However, these dietary factors and BMI associated
with Saccharomyces were not signiﬁcantly different between MS and

controls, suggesting that observed Saccharomyces difference in MS and
controls is not due to differential dietary intake or BMI between the two
groups. However, diet compositions in our study were obtained from a
food-frequency questionnaire. These self-report food intakes may introduce a certain degree of inaccuracy. Interestingly, Saccharomyces had a
positive correlation with basophils and negative correlation with regulatory B cells in pwMS’ blood. Basophils activation by Saccharomyces has
only been studied in beer allergy [53]. Whether Saccharomyces affects
pathogenesis of MS and its interaction with basophils need to be further
investigated. So far, very few studies have investigated the interaction
of commensal fungi and peripheral immune response in humans. Our
study also opens a new research question in terms of the possible relationship between Saccharomyces and regulatory B cells in MS.
Aspergillus is a genus consisting of several mould species. It is a
member of respiratory and gut mycobiome. Aspergillus produce aﬂatoxins and can cause opportunistic infections in humans [54]. Except direct
infection in CNS, it is possible that the gut Aspergillus activates a gut
immune response that indirectly affects systemic or CNS inﬂammation.
This gut response was demonstrated by the study that prolonged treatment with anti-fungal drug ﬂuconazole showing decreased level of Candida in the gut, but increased Aspergillus amstelodami, resulting in
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elevated colitis severity [55]. Aspergillus had a positive correlation with B
cells and activated CD16+ DCs in pwMS in our study. While we all
acknowledge that causal connection between the microbiome in diseases is important, we ﬁrst need to establish the association between
the mycobiome in MS, and since currently no other study reported the
role of gut mycobiome in MS. The correlation analysis in pwMS in our
study is crucial to generate future hypotheses to test mycobiomeimmune interactions in animal models and MS patients.
Fungi can have direct impact on the immune response or indirectly through their interactions with bacteria. Our study revealed a
disrupted correlation pattern between fungi and peripheral immune
proﬁle in pwMS. Correlations identiﬁed with pwMS have 1¢7 fold
fewer correlations between mycobiome and immune proﬁles than
controls’. The lack of correlation can be due to higher inter-subject
variation of the mycobiome in pwMS or loss of mycobiome-immune
homeostasis in disease status. We found Saccharomyces had a negative correlation with Lachnospiraceae incertae sedis in pwMS, raising
the possibility that the mycobiome may affect autoimmune through
regulation of bacteria. However, future studies are warranted to
determine the mechanism governing the relationship among bacteria
microbiome, mycobiome, and autoimmunity.
The stability of the fungal microbiome is hard to conclude upon.
Some studies have found that the human mycobiome is not very stable,
but some species do remain prevalent over different time points. Nash
et al. found high inter- and intra-volunteer variability in faecal fungi
over one year [5], whereas Cohen et al. did not ﬁnd changes in the fungal ﬂora in the human small intestine over several months [56]. In our
study, samples showed stability over time: 55% of pwMS had the 11
most abundant genera at both time points. For comparison, HallenAdams et al. detected common genera 27% of the time over 13 16
weeks [57]. We also found that the most common genus Saccharomyces
was detected in all MS samples at both baseline and six-month time
points. However, the changes of Saccharomyces are not consistent across
all pwMS. Instead, it showed a personalized mycobiome dynamics. We
have shown that the gut microbiome over time may exhibit a personalized changing trajectory [58]. In addition, we did not ﬁnd signiﬁcant
alterations of mycobiome in pwMS before and after DMTs treatment.
DMF, which has fungicide property, also showed no consistent effect on
the gut mycobiome because of high-intrasubject variation of the mycobiome. Together, these ﬁndings suggest a personalized mycobiome
dynamics and responsiveness to treatment.
Further studies with larger sample size and more longitudinal
time points are needed to discover the precise characteristics of the
gut mycobiome dynamics in the short and long-term in pwMS. These
will further characterise the underlying mechanisms that govern the
pattern of changes associated with DMF treatment, diet, disease
course and beyond.
The study has several limitations. It is a single centre study with a
small sample size. Future study with larger sample size and a validation cohort are warranted to conﬁrm ﬁndings on mycobiome changes
and their associations with host and bacterial microbiome. We could
not identify uniformed mycobiome changing signal after disease
modifying therapy, which can also be due to the limited number of
patients who underwent treatment during the study. In addition,
RRMS patients were mostly in the remission phase and only a few
patients were treated. Thus, we could not determine how the mycobiome could change in the active state of the disease. An additional
limitation is that the ITS Sequencing had large unclassiﬁed fungi due
to poor annotations in the fungal database.
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